RANI

Over the past six months, Rani Therapeutics' stock has experienced fluctuations, gaining 79.0% over 12 months but down 36.1% year-to-date as of September 18, 2026, with a 52-week range of $0.45 to $3.87. Key events included a Q4 and Full Year 2025 financial results call on March 26, 2026. On May 15, 2026, Q1 2026 financial results and a CFO transition led to a nearly 10% stock drop. A $20.0 million registered direct offering on May 26, 2026, caused a 12.10% decrease. Nicholas Maestas was appointed CFO on June 29, 2026, resulting in a 3.91% increase. A research and development collaboration with PegBio on July 9, 2026, led to a 1.58% decrease. Positive initial Phase 1a data for RT-114 for obesity on July 15, 2026, caused a 4.31% increase. An inducement grant was reported on July 20, 2026, with a 0.68% increase. Michelle Gilson was appointed to the Board on August 4, 2026, leading to a 2.33% increase. Participation in the Canaccord Genuity conference on August 10, 2026, saw a 1.91% decrease. Q2 2026 financial results on August 13, 2026, resulted in a slight 0.25% increase. The company announced participation in September conferences on September 8, 2026, and participated in the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. H.C. Wainwright reiterated a 'Buy' rating on September 22, 2026. Analysts have an average price target of $8.75.